Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Last trade$2.01
Day change$0.00 (0.00%)
Day range$1.96 – $2.09
Volume721,254
Market cap$159M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$159.19M
Price / earnings
15.55×
Price / book
1.92×
Price / sales
1.3×
EV / sales
0.73×
EV / EBITDA
15.05×
Profitability
Earnings per share
$0.13
Return on assets
9.42%
Return on equity
12.33%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.93×
Quick ratio
4.71×
Cash ratio
4.11×
Cash flow
Price / cash flow
32.61×
Price / free cash flow
34.76×
Free cash flow
$4.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NAGE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$27.19M
$29.79M
$31.47M
$33.84M
$33.99M
$31.12M
$30.48M
Cost of revenue
$10.09M
$10.47M
$11.5M
$12.14M
$12.06M
$10.89M
$11.15M
Gross profit
$17.11M
$19.31M
$19.98M
$21.7M
$21.93M
$20.23M
$19.33M
Selling, general and administrative
$16.9M
$17.1M
$16.92M
$17.89M
$15.9M
$15.47M
$13.3M
Research and development
$1.8M
$1.51M
$1.48M
$1.71M
$1.8M
$1.57M
$1.26M
Total operating expenses
$18.69M
$18.61M
$18.4M
$17.62M
$17.69M
$17.04M
$14.56M
Operating income
-$1.59M
$700K
$1.58M
$4.09M
$4.24M
$3.19M
$4.77M
Interest expense
$414K
$372K
$375K
$0
$564K
$552K
$459K
Income before taxes
-$1.17M
$1.07M
$6.74M
$4.42M
$4.8M
$3.74M
$5.23M
Income taxes
$0
$106K
$417K
$292K
$222K
$128K
$168K
Net income
-$1.17M
$963K
$6.32M
$4.13M
$4.58M
$3.61M
$5.06M
Net income attributable to common shareholders
-$1.17M
$963K
$6.32M
$4.13M
$4.58M
$3.61M
$5.06M
EBITDA
-$1.3M
$991K
$1.87M
$4.4M
$4.43M
$3.38M
$4.97M
Basic earnings per share
-$0.01
$0.01
$0.08
$0.05
$0.06
$0.05
$0.07
Diluted earnings per share
-$0.01
$0.01
$0.07
$0.05
$0.05
$0.04
$0.06
Recent news
Company coverage with links to the original publishers.
Niagen Bioscience reported a quarterly loss of $0.01 per share, meeting consensus estimates but missing revenue expectations by 9.81% with $27.19 million in quarterly revenues, down from $33.99 million year-over-year. The stock has declined 62.9% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
Coherus Oncology is expected to report a quarterly loss of $0.22 per share with revenues of $15.9 million when it releases Q3 2026 results on November 9. While revenues are expected to grow 37.4% year-over-year, the company has a negative Earnings ESP of -1.54% and has failed to beat consensus estimates in the last four quarters, making it an unlikely candidate for an earnings beat.
Niagen Bioscience is expected to report Q3 2026 earnings on November 4 with a projected loss of $0.01 per share and revenues declining 11.3% year-over-year to $30.15 million. The company has a negative Earnings ESP of -500% and Zacks Rank #4, making it unlikely to beat consensus estimates. The stock does not appear to be a compelling earnings-beat candidate.
Niagen Bioscience (NASDAQ: NAGE) reported doubled annual profits and 30% revenue growth for 2025, reaching $129.4 million in net sales. CEO Rob Fried announced the company is actively pursuing acquisitions and expanding into new markets including at-home injection kits and cosmetics partnerships. However, 2026 guidance of $145 million (15% growth) appears more modest, and the stock trades 60% below its 52-week high despite strong fundamentals.
The National Advertising Division reviewed claims by Reus Research for its Cata-Kor NAD+ products, finding some claims supported while recommending modifications or discontinuation of others due to insufficient substantiation of health benefits and inadequate influencer disclosures.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.